Gland Pharma Q1 Profit Jumps 43%

  Published 8 months ago

Gland Pharma reported strong Q1 FY26 results with rising profitability, improved margins, and growth across regulated markets and product launches.

  • Revenue rose 7.41% YoY to Rs 1,505.62 crore; EBITDA margin improved to 24% from 19% last year.
  • Europe, Canada, and India showed strong revenue growth; the US market declined slightly by 2.42% YoY.
  • 12 new molecules launched, 9 ANDAs approved; R&D spend stood at Rs 46 crore, 4.4% of total revenue.

You might like these

Indoco Gets EU GMP Nod for Goa Plant

EMS Wins Nagpur MMLP Contract

NITI Aayog Report: Powering India's Medium Enterprises

Bharat Dynamics Dips on Valuation Call

IDFC First Bank: ESOS Allotment Boosts Capital

KPIL Secures Major T&D Orders, Boosts FY26 Growth

NITI: US Tariffs Aid India Exports

News that matters the most ⚡